Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib. Prokoph N, Matthews JD, Trigg RM, Montes-Mojarro IA, et al. Br J Haematol 2023;202:985-994.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Prokoph N, Matthews JD, Trigg RM, Montes-Mojarro IA, et al. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib. Br J Haematol 2023;202:985-994.
PMID: 37357529